Abstract 3244
Background
Regorafenib is a multikinase inhibitor approved for the therapy of patients with metastatic colorectal carcinoma (mCRC) previously treated with a fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and (in wild-type RAS tumours) anti-EGFR therapy. The aim of the present study was to analyse the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry.
Methods
The CORECT registry (http://corect.registry.cz) is a non-interventional database of patients with colorectal cancer treated with targeted agents. The analysis included 451 evaluable patients treated with regorafenib for mCRC.
Results
The median age at diagnosis was 61.1 years. The primary tumor was in the left colon or rectum in 343 patients (76.1%), right colon in 81 patients (18.0%), data on location were not available for 27 patients (6.0%). KRAS mutation was detected in 202 patients (44.8%) and NRAS mutation in 40 patients (8.9%). The median duration of treatment was 2.7 months (range 0.0-23.4 months). Partial response was seen in 12 patients (3.2%). Progression of the disease was reported in 170 patients (44.7%) and disease stabilisation for at least 6 weeks in 110 patients (28.9%). Progression-free and overall survival data are shown in the table. Improved outcomes were observed in patients with longer interval from diagnosis of mCRC and in those without liver metastases. Age, tumor sidedness, and RAS status were not associated with outcome of regorafenib therapy. The main cause of treatment discontinuation was disease progression (71.3%) followed by general deterioration in the absence of radiological progression in 93 patients (24.5%), and adverse events related to regorafenib in (4.2%).Table: 468P
Progression-free survival and overall survival of patients treated with regorafenib
| Median (95% CI) | 3-month survival (95% CI) | 6-month survival (95% CI) | |
|---|---|---|---|
| Progression-free survival | 3.5 months (3.2–3.7) | 57.6% (52.5–62.4) | 25.2% (20.9–29.9) |
| Overall survival | 9.3 months (7.9–10.7) | 88.8% (85.2–91.5) | 68.7% (63.6–73.3) |
Conclusions
Overall survival of patients treated with regorafenib in real-world clinical practice exceeded that achieved in randomised trials.
Clinical trial identification
Legal entity responsible for the study
Katerina Kopeckova and Tomas Buchler.
Funding
The Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno received financial support for the CORECT registry from Bayer, Amgen, Merck and Roche. Supported by Grant AZV 15-26535A from the Czech Health Research Council.
Editorial Acknowledgement
Disclosure
K. Kopeckova: Research support: Bayer. B. Melichar: Consulting fees: Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen; Travel: Roche, Novartis, Astellas, Bristol-Myers Squibb; Provision of writing assistance: Roche, Bristol-Myers Squibb Payment for lectures: Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen. J. Finek: Lecture honoraria, travel grants: Roche, Merck, Pfizer, Novartis, Amgen. O. Fiala, T. Buchler: Research funding, travel grants, honoraria: Roche, Merck, Bayer, Servier, BMS, MSD, Sanofi, Amgen. J. Tomasek: Grants, consulting fees, travel: Bayer. I. Kiss: Speakers’ honoraria: Roche, Merck, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract